11:58 AM
 | 
Nov 10, 2017
 |  BC Extra  |  Company News

CHMP recommends Amgen's biosimilar Avastin

EMA's CHMP recommended approval of ABP 215 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Avastin bevacizumab, for all cancer types on Avastin's EU label: non-small cell...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >